A major challenge upon the completion of the Human Genome Project is to understand the roles that proteins play in normal and pathological processes. Large-scale proteomics efforts such as protein profiling, protein structure-determination, protein functional assignment, and protein-protein interaction analysis, are required to assign functions to the hundreds of thousands of human proteins. ProMab is a biotechnology company formed to meet these post-genomics needs. Founded and managed by a team of scientists with extensive experience in both academic and industrial biotechnology, ProMab develops and commercializes recombinant proteins and custom monoclonal antibodies through the integration of bioinformatics, gene cloning, protein expression and purification, and immunology, using novel high-throughput technologies. ProMab applies its proprietary proteins and antibodies to deliver innovative diagnostic products as well as services targeting the global biomedical market through collaborations with other biotechnology and bio-reagent companies.
ProMab aims to be one of the leading suppliers of bio-reagents in the twenty-first century and is committed to improving human health.
ProMab Biotechnologies seeks partnership with academic researchers, biotechnology and pharmaceutical companies around the world. We will achieve our distinguished global ranking within the scientific community by building a superior reputation for quality, reliability, promptness, and cost-effective products and services.